Nasdaq Stockholm's Listing Committee Has Approved Immunicum's Shares for Listing on Nasdaq Stockholm Conditional Upon Complet...
November 24 2017 - 10:30AM
Press Release
24 November 2017
Nasdaq Stockholm's Listing Committee Has Approved Immunicum's
Shares for Listing on Nasdaq Stockholm Conditional Upon Completion
of the Rights Issue
Immunicum AB
(publ; First North Premier: IMMU.ST) a biopharmaceutical company
advancing an off-the-shelf immune system primer against a range of
solid tumors, today announced Nasdaq Stockholm's listing committee
has conditionally approved Immunicum's shares for listing on Nasdaq
Stockholm. The approval is conditional upon Immunicum fulfilling
the formal listing requirement of having secured sufficient working
capital for a period of twelve months following the first day of
trading on Nasdaq Stockholm. Immunicum has previously communicated
a 90 percent secured Rights Issue of up to SEK 223 million. The
secured amount of SEK 200 million ensures that Immunicum is
financed until the end of 2019 based on planned activities.
The approval from the listing
committee is also subject to completion of customary conditions,
including the Swedish Financial Supervisory Authority's approval
and registration of a prospectus.
The subscription period for the
Rights Issue is expected to be on or about 8-22 December 2017.
Subject to the fulfilment of the above conditions, including
completion of the Rights Issue, the first day of trading on the
Nasdaq Stockholm exchange is preliminarily planned to be during
January 2018. The Company will communicate the timetable for
the listing on Nasdaq Stockholm as soon as it has been
established.
"We welcome this decision from the
Listing Committee and appreciate their guidance. I would like
to recognize the Immunicum team who has worked diligently to
maintain the requirements over the last months to support the move
to the main market," said Carlos de Sousa, CEO of Immunicum.
"We look forward to the completion of the Rights Issue and thank
our shareholders in advance for their support."
Advokatfirman Delphi acts as legal
advisor to Immunicum in connection with the listing on Nasdaq
Stockholm.
The information
is information that Immunicum is obliged to make public pursuant to
the EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact persons set out
above on 24 November 2017, at 4:30 p.m. CET.
For more information, please contact:
Carlos de Sousa, CEO,
Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com
Investor Relations Sweden
Helena Stångberg
Hallvarsson & Halvarsson
Telephone: + 46 709 71 12 53
E-mail: ir@immunicum.com
Investor and Media Relations EU/US
Gretchen Schweitzer
Trophic Communications
Telephone: +49 172 861 8540
E-mail: ir@immunicum.com
The Company's Certified Adviser is
Redeye AB
Telephone: +46 (0)8 545 013 30
www.redeye.se
About Immunicum AB (publ) Immunicum is
establishing a unique immuno-oncology approach through the
development of allogeneic, off-the-shelf cell-based therapies. Our
goal is to improve survival outcomes and quality of life by priming
the patient's own immune system to fight cancer. The company's lead
product ilixadencel, consisting of pro-inflammatory allogeneic
dendritic cells, has the potential to become a backbone component
of modern cancer combination treatments in a variety of solid tumor
indications. Founded and based in Sweden, Immunicum is publicly
traded on the Nasdaq First North Premier. www.immunicum.com
|
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Immunicum AB via Globenewswire
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Apr 2023 to Apr 2024